Continuous smoking abstinence at each follow-up period
| Levels of continuous abstinence | ||||||||
|---|---|---|---|---|---|---|---|---|
| Defined as a total of <5 cigarettes during the defined period of follow-up | ||||||||
| Varenicline | Control | |||||||
| Continuous | n | % | n | % | RR | 95% CI | p Value | Adj. p value |
| 2–52-weeks | 61 | 31.1 | 42 | 21.4 | 1.45 | 1.03 to 2.04 | 0.03 | 0.01 |
| 2–26-weeks | 78 | 39.8 | 54 | 27.6 | 1.43 | 1.07 to 1.90 | 0.02 | 0.006 |
| 2–12-weeks (EOT) | 95 | 48.5 | 71 | 36.2 | 1.32 | 1.04 to 1.67 | 0.02 | 0.01 |
Based on intention-to-treat analysis; sample size in each arm n=196.
Adj, Adjusted for baseline discipline differences (cardiology, respiratory, neurology, Vascular); EOT, End of treatment.